Clinical Trial Update: Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX® [Phase 4]

View source ↗

Summary

Phase 4 post-licensure study assessing safety and immunogenicity of ADACEL and BOOSTRIX vaccines across multiple centers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Tetanus

Drugs mentioned

• ADACEL (Tdap vaccine (tetanus, diphtheria and acellular pertussis vaccine))
• Boostrix (Diphtheria, Tetanus, and Acellular Pertussis Vaccine)

Snippet

Sponsor: Sanofi | Conditions: Pertussis, Tetanus | Phase 4 | Status: COMPLETED | Results posted: 2010-10-21